NCT06795945View on ClinicalTrials.gov

A Randomized, Double-Blind, Placebo-Controlled, Parallel Study to Evaluate the Safety of a Bovine Thymus Nuclear Extract

NAActive, not recruitingINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

February 4, 2025

Primary Completion Date

September 30, 2025

Study Completion Date

October 31, 2025

Conditions
Immunology
Interventions
DIETARY_SUPPLEMENT

TPG1

"* Thymus Nuclear Extract Dose 1 (860 mg \[2 tablets, 2x/day; total 4 tablets per day\])~* Placebo (6 tablets, 2x/day; total 12 tablets per day)"

DIETARY_SUPPLEMENT

TPG2

"* Thymus Nuclear Extract Dose 2 (2150 mg \[5 tablets, 2x/day; total 10 tablets per day\])~* Placebo (3 tablets, 2x/day; total 6 tablets per day)"

DIETARY_SUPPLEMENT

TPG3

Thymus Nuclear Extract Dose 3 (3440 mg \[8 tablets, 2x/day; total 16 tablets per day\])

DIETARY_SUPPLEMENT

Placebo

Placebo (8 tablets, 2x/day; total 16 tablets per day)

Trial Locations (1)

33615

Model Research Center, Tampa

All Listed Sponsors
collaborator

Nutrasource Pharmaceutical and Nutraceutical Services, Inc.

NETWORK

lead

Standard Process Inc.

INDUSTRY